PROC
1
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
ADC
1100%
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Whitehawk TherapeuticsMORRISTOWN, NJ
1 program1
HWK-016, MUCIN-16-targeted ADCPhase 1ADC1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2026
2027
2028
Whitehawk TherapeuticsHWK-016, MUCIN-16-targeted ADC
Clinical Trials (1)
Total enrollment: 265 patients across 1 trials
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
Start: Mar 2026Est. completion: Feb 2028265 patients
Phase 1Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 265 patients
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.